Posted by: Vanessa Dias
Friday, December 5th, 2025
The MED13L Foundation is pleased to announce the execution of a Sponsored Research Agreement with the University of California, San Francisco (UCSF) to support a new study titled “CRISPRa Proof of Concept Constructs for MED13L Haploinsufficiency.”
This agreement provides $165,000 in support for a two-year research period.
The project will explore CRISPR-based gene activation (CRISPRa) as a potential approach to increase MED13L gene expression, an area of growing interest for conditions involving haploinsufficiency. The research will help advance foundational scientific knowledge and support the broader therapeutic development landscape for MED13L Syndrome.
“This investment reflects our commitment to pursuing promising scientific avenues that may help families affected by MED13L Syndrome,” said Katie Boychuck, Board Chair of The MED13L Foundation. “We are grateful for the opportunity to support innovative academic research that can inform future therapeutic strategies.”
This agreement reinforces the Foundation’s mission to accelerate research, strengthen the scientific pipeline, and improve long-term outcomes for individuals with MED13L Syndrome.
To learn more about the Foundation’s research efforts, visit MED13L.org.
